We noticed that high expression of JMJD8 was associated with lower overall survival (OS) percentages in GBM and LGG; lower disease-specific survival (DSS) percentages of GBM, LGG, and STAD; and shortening of the progression-free interval (PFI) of ACC, LGG, and STAD. This evidence concerns the gene JMJD8 and glioblastoma.